NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $10.34 +0.01 (+0.05%) As of 01:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADMA Biologics Stock (NASDAQ:ADMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$10.26▼$10.5150-Day Range$8.46▼$10.3352-Week Range$7.21▼$20.46Volume879,791 shsAverage Volume4.19 million shsMarket Capitalization$2.31 billionP/E Ratio14.76Dividend YieldN/APrice Target$18.67Consensus RatingModerate Buy Company Overview ADMA Biologics, Inc. is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company’s operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products. ADMA’s commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases. The company also markets Nabi-HB, a hepatitis B immune globulin used to help prevent hepatitis B infection in certain clinical situations. Headquartered in Boca Raton, Florida, ADMA serves the U.S. specialty pharmaceutical and healthcare markets through its plasma collection, manufacturing and commercial operations. The company was founded in 2004 and is led by President and Chief Executive Officer Adam S. Grossman.AI Generated. May Contain Errors. Read More ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 66% of companies evaluated by MarketBeat, and ranked 255th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingADMA Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialADMA Biologics has a consensus price target of $18.67, representing about 80.6% upside from its current price of $10.34.Amount of Analyst CoverageADMA Biologics has only been the subject of 3 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.97% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 8.97% in the coming year, from $0.78 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 14.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 14.76, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.59.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.25% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 10.81, which indicates bearish sentiment.Change versus previous monthShort interest in ADMA Biologics has recently increased by 1.41%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentADMA Biologics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ADMA Biologics this week, compared to 8 articles on an average week.Search InterestOnly 10 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat Follows5 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders3.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADMA Stock News HeadlinesADMA Biologics Inc (NASDAQ:ADMA) Stock Has Consensus Target Price of $18.67 According to AnalystsOctober 5, 2026 | americanbankingnews.comContrasting ADMA Biologics (NASDAQ:ADMA) & PTC Therapeutics (NASDAQ:PTCT)September 30, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 9 at 1:00 AM | Chaikin Analytics (Ad)ADMA Biologics (ADMA), Why Is It Back In The Spotlight?September 27, 2026 | finance.yahoo.comBerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)September 8, 2026 | prnewswire.comADMA Biologics: Maybe The Bears Are Right (Rating Downgrade)September 2, 2026 | seekingalpha.comBerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)August 31, 2026 | prnewswire.comADMA Biologics, Inc. (ADMA) Stock Earnings Call Transcripts - Yahoo FinanceAugust 23, 2026 | finance.yahoo.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $18.24 on January 1st, 2026. Since then, ADMA stock has decreased by 43.3% and is now trading at $10.3350. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) posted its earnings results on Wednesday, August, 5th. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by $0.00. The business's revenue was up 2.0% on a year-over-year basis. Read the conference call transcript. When did ADMA Biologics IPO? ADMA Biologics (ADMA) raised $30 million in an initial public offering (IPO) on the week of November 10th 2014. The company issued 3,352,941 shares at a price of $8.50-$9.50 per share. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional shareholders include City Center Advisors LLC (0.02%), GAMMA Investing LLC and Farther Finance Advisors LLC. Insiders that own company stock include Adam S Grossman, Steve Elms, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade and Lawrence P Guiheen. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/05/2026Today10/09/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ADMA's financial health is in the Red zone, according to TradeSmith. ADMA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees647Year Founded2004Price Target and Rating Average Price Target for ADMA Biologics$18.67 High Price Target$21.00 Low Price Target$17.00 Potential Upside/Downside+80.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio14.78 Forward P/E Ratio13.24 P/E GrowthN/ANet Income$146.93 million Net Margins32.98% Pretax Margin42.26% Return on Equity40.17% Return on Assets26.97% Debt Debt-to-Equity Ratio0.49 Current Ratio6.97 Quick Ratio3.81 Sales & Book Value Annual Sales$510.17 million Price / Sales4.53 Cash Flow$0.67 per share Price / Cash Flow15.50 Book Value$2.01 per share Price / Book5.14Miscellaneous Outstanding Shares223,990,000Free Float215,250,000Market Cap$2.31 billion OptionableOptionable Beta0.70 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ADMA) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
